Neuroscience
...it's not set to GO yet!
Oops, it seems that someone [The Lane Communications Group??] jumped the gun in submitting this press release for publication, because the company's website isn't ready yet:
Their product? It's REALLY a big deal, if it turns out to be true:
Gonzalo Laje, Silvia Paddock, Husseini Manji, A. John Rush, Alexander F. Wilson, Dennis Charney, and Francis J. McMahon (2007). Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. Am J Psychiatry 164:1530-1538.
Yesterday, World of Psychology had a post about this paper:
- By Treating Depression, Do We Also Treat Suicidality? The Answer Is Far From Straightforward
By guest blogger James Coyne. Edgar Allan Poe’s fictional detective C. Auguste Dupin warns against tackling questions that are too complicated to test, but too fascinating to give up. Whether psychotherapy or medication can reduce suicidality is...
- What's Different About Those Who Attempt Suicide Rather Than Just Thinking About It?
Only a minority of people who think about committing suicide actually go ahead and make a suicide attempt. Is there something different about these people – some way, perhaps, to identify those suicidal people who are at most risk? Kate Fairweather...
- Neuropsychology Abstract Of The Day: Suicidal Behavior And Semantic Dementia
Suicidal Behavior in Dementia: A Special Risk in Semantic Dementia. American Journal of Alzheimer's Disease and Other Dementias. 2013 Jul 1; Sabodash V, Mendez MF, Fong S, & Hsiao JJAbstractBackground: Some studies report a low suicide risk in general...
- Neuropsychology Abstract Of The Day: Suicide Assessment
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry. 2011 Dec;168(12):1266-77. Posner K, Brown GK, Stanley B, Brent DA,...
- Strattera (atomoxetine) And Attention Deficit Disorder
A press release from the Food and Drug Administration (FDA):FOR IMMEDIATE RELEASE P05-65 September 29, 2005 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Strattera (Atomoxetine) for...
Neuroscience
On Your NeuroMark, Get Set...
...it's not set to GO yet!
Oops, it seems that someone [The Lane Communications Group??] jumped the gun in submitting this press release for publication, because the company's website isn't ready yet:
NeuroMark
We are very sorry to inconvenience you. However, the informational site we are preparing for the Mark-C test for predicting risk for suicidal ideation when taking Citalopram is scheduled to be available on October 1st.
The availability of our test was to be announced October 1st to the national media. However, through an inadvertent technical error, the American Journal of Psychiatry publication was published online October 27th [sic], ahead of the October 1st embargoed date.
We are working diligently to make our site available to you as quickly as we can....
Their product? It's REALLY a big deal, if it turns out to be true:
Genetic test announced for suicidal ideation in patients using antidepressant drugsHere's the relevant citation in the American Journal of Psychiatry:
Safer prescribing anticipated
Boulder, CO, October 1, 2007 – NeuroMark, a Boulder, Colorado company, announced today the immediate availability of a genetic test to identify people at risk of suicidal ideation—thoughts of committing suicide—when prescribed an antidepressant drug. The test, called the Mark-C™ test, is expected to help restore public confidence in antidepressant medication and help to reduce a recently announced spike in suicide rates among U.S. youth. “This is an exciting example of the power of genetics to address a critical need and make important drugs safer for patients worldwide,” stated Kim Bechthold, NeuroMark’s CEO.
In September 2007, the Centers for Disease Control (CDC), announced that in 2004 there was a 8% rise in suicide rates among 10-19 year olds, the year that the FDA issued public health warnings linking antidepressant drugs with suicidal ideation and behavior. "The largest percentage increase in rates from 2003 to 2004 was among females aged 10—14 (75.9%), followed by females aged 15—19 years (32.3%) and males aged 15—19 years (9%)," according to the CDC.
In a statement, the company said, “We feel a sense of responsibility, given the current climate, to provide the test to physicians immediately so that they may identify patients who would benefit from closer monitoring or even a change in therapy. It is our hope that this early test will encourage more people to consider antidepressant drug treatment who would benefit from it."
"Before the NeuroMark test, we couldn’t differentiate between the subset of patients who were at risk of suicidal ideation and those who could more safely take an antidepressant drug," stated NeuroMark president Dr. Peter Tolias. “The Mark-C test is highly predictive and identifies citalopram-treated patients who are at high risk for suicidal ideation. The test also identifies people at low risk, giving the physician more confidence in prescribing citalopram," he added.
Gonzalo Laje, Silvia Paddock, Husseini Manji, A. John Rush, Alexander F. Wilson, Dennis Charney, and Francis J. McMahon (2007). Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. Am J Psychiatry 164:1530-1538.
Yesterday, World of Psychology had a post about this paper:
Suicidal Genes DiscoveredWhy yes, that rumor appears to be true.
By John M. Grohol, Psy.D.
September 26th, 2007The Oct. 1 issue of The American Journal of Psychiatry will release both a study and editorial suggesting that a set of suicidal gene markers have been discovered. That is, people with these markers have a higher incidence of suicidal thinking (which is often the precursor to suicidal action). This is a significant finding, since there has been little previous evidence that suicidal thoughts or behaviors might be coded all the way down into our genes.
. . .
Rumor has it that a company will also be marketing a genetic test kit for this set of “suicide markers.”
- By Treating Depression, Do We Also Treat Suicidality? The Answer Is Far From Straightforward
By guest blogger James Coyne. Edgar Allan Poe’s fictional detective C. Auguste Dupin warns against tackling questions that are too complicated to test, but too fascinating to give up. Whether psychotherapy or medication can reduce suicidality is...
- What's Different About Those Who Attempt Suicide Rather Than Just Thinking About It?
Only a minority of people who think about committing suicide actually go ahead and make a suicide attempt. Is there something different about these people – some way, perhaps, to identify those suicidal people who are at most risk? Kate Fairweather...
- Neuropsychology Abstract Of The Day: Suicidal Behavior And Semantic Dementia
Suicidal Behavior in Dementia: A Special Risk in Semantic Dementia. American Journal of Alzheimer's Disease and Other Dementias. 2013 Jul 1; Sabodash V, Mendez MF, Fong S, & Hsiao JJAbstractBackground: Some studies report a low suicide risk in general...
- Neuropsychology Abstract Of The Day: Suicide Assessment
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry. 2011 Dec;168(12):1266-77. Posner K, Brown GK, Stanley B, Brent DA,...
- Strattera (atomoxetine) And Attention Deficit Disorder
A press release from the Food and Drug Administration (FDA):FOR IMMEDIATE RELEASE P05-65 September 29, 2005 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Strattera (Atomoxetine) for...